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O-GlcNAcylation is a post-translational modification catalysed by O-GlcNAc
transferase (OGT). Missense mutations in OGT have been associated with
developmental disorders, OGT-linked congenital disorder of glycosylation
(OGT-CDG), which are characterized by intellectual disability. OGT relies
on the hexosamine biosynthetic pathway (HBP) for provision of its UDP-
GlcNAc donor. We considered whether mutations in UDP-N-acetylhex-
osamine pyrophosphorylase (UAP1), which catalyses the final step in the
HBP, would phenocopy OGT-CDG mutations. A de novo mutation in UAP1
(NM_001324114:c.G685A:p.A229T) was reported in a patient with intellec-
tual disability. We show that this mutation is pathogenic and decreases the
stability and activity of the UAP1 isoform AGX1 in vitro. X-ray crystallog-
raphy reveals a structural shift proximal to the mutation, leading to a confor-
mational change of the N-terminal domain. These data suggest that the
UAP1A229T missense mutation could be a contributory factor to the patient
phenotype.
Keywords: enzyme mutation; neurodevelopment; O-GlcNAcylation;
pathogenesis; protein structure
O-linked b-N-acetylglucosamine (O-GlcNAc) is a post-
translational modification that occurs on thousands of
nuclear and cytoplasmic proteins. The dynamic cycling
of O-GlcNAc is regulated by a single pair of enzymes,
the O-GlcNAc transferase (OGT), which transfers the
GlcNAc moiety from UDP-GlcNAc to Ser/Thr of pro-
tein targets [1], and O-GlcNAcase, which removes O-
GlcNAc from the modified proteins [2]. Protein O-
GlcNAcylation is involved in various physiological
processes, such as transcription, nutrient sensing and
cell signalling [3–7]. In Caenorhabditis elegans, O-
GlcNAc orchestrates metabolism through the insulin-
signalling pathway to maximize neuron regeneration in
response to neuronal injury [8]. The Drosophila OGT
homologue is encoded by super sex combs, which is
required for the repression of Polycomb genes [9], a
cluster of genes essential for the development of ani-
mals and plants by dynamically regulating chromatin
modification [10–12]. Deletion of either the Ogt or the
Oga gene leads to embryonic lethality in mice [13,14].
O-GlcNAcylation is involved in neurodegenerative dis-
eases, such as Alzheimer’s disease [15], amyotrophic
lateral sclerosis [16] and Parkinson’s disease (PD)
[17,18]. Recently, dysregulation of O-GlcNAcylation
caused by OGT gene mutations has been associated
with a developmental disorder termed OGT-linked
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congenital disorder of glycosylation (OGT-CDG) with
patients characterized by intellectual disability and
developmental delay [19–23].
UDP-GlcNAc, the substrate of OGT, is the end
product of the hexosamine biosynthetic pathway
(HBP) (Fig. 1) that is present in all three kingdoms of
life [24–26]. The first and rate-limiting step of the HBP
is catalysed by glucosamine-fructose-6-phosphate
aminotransferase 1 (GFAT) which transfers an amino
group from glutamine to fructose-6-phosphate to pro-
duce glucosamine-6-phosphate. Glucosamine-6-phos-
phate then turns into GlcNAc-6-phosphate by the
action of glucosamine-6-phosphate N-acetyltransferase
(GNA1). The third step is catalysed by phosphogluco-
mutase 3 (PGM3) that converts GlcNAc-6-phosphate
into GlcNAc-1-phosphate. Finally, the production of
UDP-GlcNAc is reversibly catalysed by UDP-N-
acetylhexosamine pyrophosphorylase (UAP1) which
uses GlcNAc-1-phosphate and UTP as substrates in
the forward reaction to produce UDP-GlcNAc and
pyrophosphate.
There are several lines of evidence that HBP is
essential for development. GFAT gene knockout cells
cannot survive without supplementation of the enzyme
product, GlcNAc [27]. GFAT gene mutations have
been linked to congenital myasthenic syndromes [28], a
group of conditions owing to the defect of signal
transmission from nerve cells to muscles [29]. GFAT
patients displayed reduced levels of GFAT protein and
O-GlcNAcylation [28]. Inactivation of GNA1 in
mouse embryonic fibroblasts led to defects in UDP-
GlcNAc biosynthesis, O-GlcNAc modification and cell
proliferation [30]. In addition, mutations of the PGM3
gene that resulted in compromised enzymatic activity
were identified as a cause of immunodeficiency, skele-
tal dysplasia and neurocognitive impairment [31–33].
A study in Drosophila showed that mutation of
nesthocker, the orthologue of the PGM3 gene, resulted
in decreased levels of cytoplasmic UDP-GlcNAc, dis-
rupted protein O-GlcNAcylation and finally blocked
mesodermal development [34]. In Drosophila, the
UAP1 gene orthologue mummy modulates
Fig. 1. The eukaryotic HBP. The four main enzymes of the pathway are coloured in red, and metabolites generated by the HBP are
coloured in blue. Reversible and irreversible reactions are indicated with double- and single-headed arrows, respectively
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decapentaplegic (Dpp) signalling in the embryonic epi-
dermis and is required for epithelial morphogenesis
and nervous system development [35–37]. These data
collectively suggest a link between the perturbation of
the HBP, protein O-GlcNAcylation and neurodevelop-
ment.
The human UAP1 gene encodes two different iso-
forms, named AGX1 and AGX2, with AGX1 being
more abundant in testis and AGX2 in somatic tissues
[38]. The two isoforms differ by a 17-amino acid inser-
tion in the C terminus of AGX2. Compared to AGX2,
AGX1 has similar efficiency in producing UDP-
GlcNAc and 50 times more efficiency in producing
UDP-GalNAc [39]. Structural characterization revealed
that both AGX1 and AGX2 comprise three domains,
that is N-terminal, catalytic and C-terminal domain,
and the 17-amino acid insertion in the C-terminal
domain of AGX2 ablated oligomeric assembly [40].
UAP1 genes, designated glmU in bacteria, have been
reported to be essential in both prokaryotes and
eukaryotes [41,42]. For instance, inactivation of GlmU
thermosensitive mutant in Escherichia coli resulted in a
37% reduction in peptidoglycan content and cell lysis
[43]. The fungal UAP1 gene orthologue UAP is essen-
tial in both Saccharomyces cerevisiae and Aspergillus fu-
migatus [44,45]. Because the action of OGT depends on
the steady supply of cytoplasmic UDP-GlcNAc through
the HBP, we considered whether UAP1 gene mutations
would phenocopy OGT-CDG mutations.
As a clinical genetics programme, the Deciphering
Developmental Disorders Study (DDD) was recently
established to investigate undiagnosed developmental
disorders using exome sequencing and array-based detec-
tion of chromosomal rearrangements [46]. A de novo
heterozygous mutation in the UAP1 gene (NM_
001324114:c.G685A:p.A229T, DDD entry: https://deci
pher.sanger.ac.uk/ddd/research-variant/c9774b30226f59f
8c1f79a7578fe5fc3/overview), which encodes a missense
variant UAP1A229T, has been identified in a patient
from the DDD study with reported cranial and skeletal
abnormalities and intellectual disability. Here, we inves-
tigate possible effects of the A229T mutation on AGX1
using various in vitro approaches. First, clinical bioin-
formatics tools predict that the mutation is likely to be
pathogenic, while biochemical analysis with recombi-
nant AGX1A229T reveals that the A229T mutation
causes a reduction of protein thermal stability. Com-
pared to wild-type AGX1, AGX1A229T has lower activ-
ity in producing UDP-GlcNAc. X-ray crystallographic
structural characterization demonstrates that the A229T
mutation lies proximal to the active site. The mutation
induces local structural shift which weakens the hydro-
gen bond network connecting the N-terminal and
catalytic domain, leading to conformational changes of
the N-terminal domain that explains changes in cat-
alytic activity. Together, these in vitro data suggest that
the UAP1A229T missense mutation could contribute to
the patient phenotype.
Materials and methods
Construct cloning, protein expression and
purification
The construct with full-length AGX1 (UniProt Q16222)
cloned into pGEX6P4 (expressing GST-tagged protein) was
obtained from our lab stock [47]. The A229T mutation was
introduced using site-directed mutagenesis with forward
primer ggtggtctttatcggAcacttgcagcccag and reverse primer
ctgggctgcaagtgTccgataaagaccacc. All constructs were veri-
fied by sequencing.
E. coli (DE3) pLysS was used for recombinant expres-
sion of N-terminally GST-tagged AGX1wt and AGX1A229T.
Protein expression was induced at 18 °C by addition of
200 µM IPTG when absorbance at OD600 reached 0.6 and
incubated for a further 16 h. Cells were harvested by cen-
trifugation at 4200 rmin1 at 4 °C for 30 min and then
resuspended in lysis buffer (100 mM Tris, 150 mM NaCl,
0.5 mM TCEP pH 7.5, 0.1 mgmL1 lysozyme, 0.1 µgmL1
DNase, 1 mM benzamidine, 0.2 mM PMSF and 5 µM leu-
peptin). Cells were lysed using French Press with a pressure
of 50 000 psi. Cell lysate was then spun down at
20 000 rmin1 at 4 °C for 30 min in an Avanti J-25 cen-
trifuge (Beckman). The supernatant was incubated with
Glutathione-Sepharose beads (GE Healthcare) at 4 °C for
2 h, and beads were then washed with 4–5 column volumes
of lysis buffer. Bound protein was cleaved overnight from
GST beads by PreScission protease at a final concentration
of 0.5 µM. Protein was pooled then concentrated to 5 mL
before loading onto a pre-equilibrated Superdex 200 26/60
preparative column (AKTA Prime system used; GE
Healthcare). Fractions containing pure protein were pooled
and concentrated to 0.5 mL using a 50 kDa 20 mL Vivas-
pin concentrators. Protein was quantified using NanoDrop
and then flash-frozen in liquid nitrogen.
Differential scanning fluorimetry assay
Assays were performed with 2 µM protein (1 mgmL1), 5
9 SYPRO Orange dye (Sigma) and 1 mM ligand in the
assay buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2 mM
MgCl2 and 0.5 mM TCEP) in a total volume of 25 µL. Flu-
orescence (kex = 530 nm, kem = 560 nm) was monitored
with a Bio-Rad (CFX ConnectTM) real-time system, while
system temperature was increased from 20 to 90 °C in 1 °C
increments. Data were fitted to Boltzmann sigmoidal curve
using GRAPHPAD PRISM 6 to obtain Tm, which is the
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inflection point of the curve. Assays were performed with
six biological replicates, and each biological replicate con-
tained three technical replicates.
Enzymatic activity assay
A coupled enzyme assay was deployed to study steady-state
kinetics. In the assay, AGX1wt utilizes UTP and GlcNAc-1P
to produce UDP-GlcNAc and pyrophosphate; pyrophos-
phate is then degraded by pyrophosphatase (coupling
enzyme) into inorganic phosphate. BIOMOL Green
reagent (0.03% w/v malachite green, 0.2% w/v ammonium
molybdate and 0.5% v/v Triton X-100 in 0.7 N HCL) was
used to detect the inorganic phosphate produced [48]. To
determine Michaelis–Menten parameters, the assay was per-
formed in triplicate with each reaction in a total volume of
100 µL buffer containing 50 mM Tris, pH 7.5, 10 mM
MgCl2, 10% (v/v) glycerol, 1 mM DTT, 0.05 units pyrophos-
phatase and 20 nM AGX1, and one of the two substrates
was kept at an excess concentration (500 µM), while the
other one varied from 0 to 500 µM. Reactions were initiated
by the addition of 20 nM AGX1wt/ AGX1A229T and then
incubated at room temperature for 10 min. Reactions were
terminated by the addition of 100 µL BIOMOL Green
reagent. The assay plate was kept at room temperature for
30 min to allow colour development. The absorbance at
620 nm was measured using a Spectra max 340 PC. The
assay was performed with five biological replicates, and each
biological replicate contained three technical replicates. The
turnover of substrates was < 10% under all conditions
tested. Data were analysed using GRAPHPAD PRISM to calcu-
late Km, Vmax and P-values.
An XBZ (xanthene-based Zn) assay was developed to
probe the activity of AGX1wt and AGX1A229T catalysing
the reverse reaction. In the XBZ assay, the fluorescent
probe XBZ is activated once it binds to UTP [49]. The high
sensitivity and selectivity of XBZ for NTP over NDP-sug-
ars and sugar-phosphates has been demonstrated previously
[49,50]. Since pyrophosphate is one of the substrates of
AGX1 in the reverse reaction and, in addition to UTP, it
also induces XBZ fluorescence [49], we showed that 50 µM
pyrophosphate was thoroughly degraded into inorganic
phosphate after incubation with 0.05 U pyrophosphatase at
room temperature for 30 min (Fig. S5A). A UTP standard
curve was obtained using a UTP standard that was pur-
chased from Sigma (catalog no. U6625) and serially diluted
in the buffer containing 50 mM Tris pH 7.5, 0.5 mM MgCl2,
2% (v/v) glycerol, 20 µM pyrophosphate, 40 µM UDP-
GlcNAc and 0.05 U pyrophosphatase in a total volume of
100 µL (Fig. S5B). Plates were placed at room temperature
for 30 min to allow the development of background sig-
nals. For measuring the reverse reaction catalysed by
AGX1wt and AGX1A229T, assays were performed in mix-
tures containing 50 mM Tris pH 7.5, 2% (v/v) glycerol,
0.5 mM MgCl2, 40 µM UDP-GlcNAc and 20 µM
pyrophosphate in a total volume of 100 µL. Reactions were
initiated by addition of 0.5 nM enzyme and then incubated
at room temperature for 1 min. Reactions were terminated
by boiling for 5 min. After cooling down to room tempera-
ture, reactions were then supplied with 0.05 U pyrophos-
phatase (in a volume of 5 µL) and incubated further at
room temperature for 30 min to allow thorough degrada-
tion of unconsumed pyrophosphate. XBZ was prepared at
15 µM in a buffer containing 25 mM HEPES pH 7.5,
10 mM NaCl, 75 µM pyrocatechol violet and 50% (v/v)
methanol. Two hundred microlitre XBZ solution was
added to each assay, and fluorescence was measured using
a Spectra max 340 PC with kex and kem set as 485 and
530 nm, respectively. The turnover of both substrates was
below 10%. Data analysis was performed using GRAPHPAD
PRISM.
Crystallization and structure solution
Before setting up crystal trays, AGX1A229T (10 mgmL1)
was buffer exchanged into crystallization buffer containing
25 mM Tris, pH 7.5, which is similar to the crystallization
buffer of wild-type AGX1 [40]. Crystallization was set up in
sitting drop format with each drop containing 0.3 µL reser-
voir solution and 0.2 µL protein. Crystals appeared in 0.2 M
MgCl2, 0.1 M Tris, pH 8.5 and 30% PEG 4000 within
3 days. Crystals were flash-frozen in liquid nitrogen and sent
to the I24 beamline of the UK National Synchrotron (Dia-
mond Light Source) for data collection. Data sets were
indexed and integrated with iMOSFLM [51]. The phase
problem was solved by molecular replacement using MOL-
REP [52] and the PDB 1JV1 [40] as a phase donor. The
structure was refined using REFMAC5 [53] and built manu-
ally using COOT [54]. PYMOL [55] was used to generate figures.
Bioinformatics analysis
UniProt IDs of protein sequences used to construct the phy-
logenetic tree are: F1S210 (Sus scrofa), F1MJP7 (Bos tau-
rus), Q16222 (Homo sapiens), Q91YN5 (Mus musculus),
F1QZD3 (Danio rerio), F6SUV5 (Xenopus tropicalis),
F1NFV9 (Gallus gallus), Q9Y0Z0 (Drosophila melanogaster),
Q54GN5 (Dictyostelium discoideum), Q940S3 (Arabidop-
sis thaliana), Q386Q8 (Trypanosoma brucei brucei), Q18493
(C. elegans) and P43123 (S. cerevisiae). A phylogenetic tree
was calculated by CLUSTALX [56] and visualized using MEGA7
[57] with topology displayed. Protein sequences were aligned
using JALVIEW [58].
Results
UAP1 A229T mutation is potentially pathogenic
In diploid organisms, haploinsufficiency is a phe-
nomenon in which a single copy of a functional gene
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is not sufficient to produce the normal/wild-type
phenotype. Since the patient is only heterozygous for
the UAP1 A229T missense mutation (DDD entry:
https://decipher.sanger.ac.uk/ddd/research-variant/c9774b
30226f59f8c1f79a7578fe5fc3/overview), we first investi-
gated whether the UAP1 gene is associated with hap-
loinsufficiency. Haploinsufficiency score (HI index) is
the predicted probability of a gene to be haploinsuffi-
cient and over 80% of protein-coding genes in the
human genome have been scored ranging from 0 (hap-
loinsufficient) to 100% (haplosufficient) [59]. Based on
the analysis of protein-coding genetic variation in
60 706 humans, the loss intolerance (pLI) is computed
to predict the probability of a gene to be loss-of-func-
tion (LoF) intolerant [60]. High pLI scores (pLI ≥ 0.9)
indicate LoF intolerance, whereas low pLI scores
(pLI ≤ 0.1) indicate LoF tolerance. The predicted HI
and pLI of the UAP1 gene are 42.14% and 0.91,
respectively, which suggests that the UAP1 gene is
potentially haploinsufficient and LoF intolerant.
To investigate whether the UAP1 A229 mutation is
tolerated in an evolutionary context, primary
sequences of eukaryotic UAP1 orthologues were
aligned. The data show that A229 is conserved in all
eukaryotes (Figs 2 and S1), suggesting an important
structural and/or functional role. In addition to
sequence analysis, the UAP1 A229T mutation was pre-
dicted to be pathogenic by in silico tools, such as SIFT
[61] (score = 0.03) and Polyphen-2 [62] (score = 1)
which evaluate effects of amino acid substitutions on
proteins and MutationTaster [63] (P value = 1) which
predicts the pathogenic potential of the DNA muta-
tion. Together, these data suggest that the heterozy-
gous UAP1 A229T mutation is potentially pathogenic.
The A229T mutation decreases AGX1 stability
We next investigated the possible effects of the A229T
mutation on the biochemical properties of AGX1.
AGX1A229T was generated by site-directed mutagene-
sis, and GST-tagged AGX1wt and AGX1A229T were
recombinantly expressed in E. coli and purified
through glutathione-affinity and size exclusion chro-
matography. During protein purification, it was
noticed that AGX1A229T was prone to forming aggre-
gates in solution, which may explain the lower protein
yield (1.0 mgL1 of culture) compared to AGX1wt
(4.5 mgL1 of culture). To examine whether this was
the result of intrinsic AGX1A229T stability, we analysed
the thermal stability of AGX1wt and AGX1A229T using
a differential scanning fluorimetry assay (DSF). This
revealed that, compared to AGX1wt, AGX1A229T was
less stable as indicated by a reduction of the melting
temperature (Tm) by approximately 5.3 °C (Fig. 3A).
DSF can also be used to observe protein–ligand inter-
actions, which often increase the melting temperature
[64,65]. The melting temperatures of both AGX1wt
and AGX1A229T were increased by incubation with the
substrates/products, that is UTP, GlcNAc-1P and
UDP-GlcNAc (Fig. 3B), suggesting that AGX1A229T
retains the ability to bind these substrates. Of note,
AGX1A229T was less stable than AGX1wt regardless of
which ligand was supplemented (Fig. 3B). Hence, these
data suggest that the A229T mutation decreases
AGX1 stability in vitro.
The A229T mutation affects AGX1 activity
Given that A229 is conserved in eukaryotic UAP1
orthologues (Figs 2 and S1), and the A229T mutation
resides in the catalytic domain, we next investigated
the potential effects of the A229T mutation on the
steady-state kinetics of AGX1 catalysing the forward
reaction. The reaction was monitored through a colori-
metric assay using pyrophosphatase as the coupling
enzyme, which hydrolyses the AGX1 pyrophosphate
product leading to free inorganic phosphate that can
be detected with Biomol Green [48]. The results show
that, compared to AGX1wt, AGX1A229T has a twofold
Fig. 2. Sequence alignment of eukaryotic UAP1s. Sequences are
named as organism abbreviation followed by sequence region. The
phylogenetic tree was constructed based on full-length proteins
using CLUSTALX [56] and then visualized with MEGA7 [57]. A229 is
highlighted in a red box. DANRE, Danio rerio; XENTR,
Xenopus tropicalis; DROME, Drosophila melanogaster; DICDI,
Dictyostelium discoideum; ARATH, Arabidopsis thaliana; TRYB2,
Trypanosoma brucei brucei (strain 927/4 GUTat10.1); CAEEL,
Caenorhabditis elegans.
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increased Km (P < 0.01, t-test) towards both substrates
(i.e. UTP and GlcNAc-1P) and decreased catalytic effi-
ciency in utilizing UTP (P = 0.0382, t-test) (Fig. 3C,
D). To enable comparison of AGX1wt and AGX1A229T
activity in catalysing the reverse reaction, we used a
xanthene-based Zn (XBZ) fluorophore, which fluo-
resces upon binding of the reaction product UTP [49].
In this assay, AGX1A229T is more active than AGX1wt
in consuming UDP-GlcNAc and pyrophosphate
(P = 0.0359, t-test, Fig. 3E). Together, these data sug-
gest that the A229T mutation affects AGX1 activity
which may result in lower UDP-GlcNAc levels in vivo.
The A229T mutation induces structural changes
We next determined the crystal structure of
AGX1A229T to investigate the structural consequences
of substituting the conserved A229 with a threonine.
We were unsuccessful in obtaining the AGX1A229T
crystals using the published AGX1wt crystallization
condition [40]. However, crystals of AGX1A229T in
complex with UDP-GlcNAc were obtained from
screening commercial crystallization conditions, and
synchrotron diffraction data were collected to 1.7 A
(Table 1). The structure was solved by molecular
replacement using the published AGX1 structure
(PDB: 1JV1 [40]) as a search model and refined to
R = 0.187, Rfree = 0.226. AGX1
A229T crystallized with
two molecules in a P1 unit cell. Structural superposi-
tion of AGX1A229T and AGX1wt revealed conforma-
tional differences (pairwise RMSDs of the A and B
chains 0.4–1.0 A, Fig. S2) in the N-terminal domain of
both chains (Fig. 4A,B). In addition, the uridine moi-
ety of UDP-GlcNAc binding in the active site of the
AGX1A229T B chain points to the outside of the sub-






Fig. 3. In vitro characterization of recombinant AGX1A229T. (A) Thermal denaturation curve showing unfolded fraction of recombinant AGX1wt
and AGX1A229T as a function of temperature. Data were fitted to Boltzmann sigmoidal curve equation, with error bars representing SEM of
six biological replicates. (B) Melting temperature (Tm) of AGX1
wt and AGX1A229T in the absence or presence of ligand. (C), (D) Km and kcat/Km
of AGX1wt and AGX1A229T utilizing UTP and GlcNAc-1P. Error bars represent SEM of five biological replicates. *P = 0.0382, **P = 0.0036,
***P < 0.001, t-test. (E) Activity assay for the AGX1wt and AGX1A229T reverse reaction. Error bars represent SEM of three biological
replicates. *P = 0.0359, t-test.
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conformation of UDP-GlcNAc binding in the active
site of the AGX1A229T A chain and AGX1wt (Fig. 4B).
We suggest that the conformational changes in the
AGX1A229T B chain are due to an alkylation of
Cys251 in the active site that displaces UDP-GlcNAc
(Fig. 4B). We consider this alkylation to be artefactual
as carbamidomethylation on multiple cysteines of both
AGX1wt and AGX1A229T was observed with peptide
mass fingerprinting (Table S1). Since our aim was to
investigate the structural consequences of substituting
the conserved A229 with a threonine, we focused on a
detailed comparison of AGX1wt A chain with its
AGX1A229T equivalent.
In line with the decreased catalytic efficiency of
AGX1A229T in consuming UTP (Fig. 3D), the A229T
mutation is in the middle of the a-helix that coordi-
nates the uridine moiety of UDP-GlcNAc (Fig. 4C).
In AGX1A229T structure, there is a shift of 1.2 A in
the position of R228 (the residue next to A229)
towards the N terminus and a shift of 1.8 A in the C
terminus of the helix encompassing the mutation to
the opposite face of A229 (pushing effect) (Fig. 4C).
In the A and B chains of AGX1wt, R228 interacts with
E44 through two hydrogen bonds (3.0 and 3.1 A in A
chain; 3.3 and 2.6 A in B chain), which contributes to
the interaction between the N-terminal and catalytic
domain (Fig. S3). The R228-E44 interaction is abol-
ished in the AGX1A229T structure caused by the posi-
tion shift of R228 (Fig. 4F). The pushing effect is
likely due to the bulkier side chain of threonine com-
pared to that of alanine. In AGX1wt, the distances
between the side chain of A229 and the main chain of
Q195 and Q196 are 3.7 and 3.6 A, respectively. How-
ever, In AGX1A229T structure these distances are
reduced to 2.7 and 2.2 A, respectively, which is below
the C-O Van der Waals diameter (3.27 A [66]). Since
alanine has high helix propensity while threonine has
high b-sheet propensity [67], we then investigated
whether the A229T mutation could cause distortion of
this key active site a-helix. We aligned the AGX1A229T
A chain with eukaryotic UAP1 orthologues at the
point of the mutation. The results showed that, in the
aligned sequences, even though there are sequence
variations at positions apart from A229 and L230, the
AGX1A229T A chain retains the a-helical conformation
around position 229 (Fig. 4E). Together, the A229T
mutation induced a local structural shift without dis-
rupting the secondary structure of AGX1.
In a global structural view, the A229T mutation
causes the N-terminal domain of AGX1A229T A chain
to adopt an open/relaxed conformation compared to
that of AGX1wt (Fig. 4A,F). In AGX1wt B chain, a
distant interaction between Q112 in the catalytic loop
and M218 in the N-terminal domain is mediated by
R169 through hydrogen bonds (3.3 and 3.1 A). The
Q112-R169-M218 interaction was observed in the
AGX1wt B chain but not A chain (Fig. S3), which
probably indicates the interaction is dynamic in solu-
tion or catalysis. Along with the conformational
change of the N-terminal domain in the AGX1A229T
structure, is M218 shifted by 0.8 A away from R169,
weakening the Q112-R169-M218 interaction (Fig. 4F).
Together, the data suggest considerable conforma-
tional changes induced by the A229T mutation.
Discussion
UAP1 is the last enzyme in the HBP, reversibly con-
verting UTP and GlcNAc-1P to UDP-GlcNAc and
pyrophosphate. The steady supply of cytoplasmic
UDP-GlcNAc is not only required for normal cellular
physiology [43–45], but also essential for development
[28,31–33]. O-GlcNAcylation is one of the PTMs that
depends on the steady supply of cytoplasmic UDP-
GlcNAc. There is accumulating evidence that
Table 1. Scaling and model-building statistics of the AGX1A229T
crystal structure. Values in brackets are for the highest resolution
shell.
Data collection
Space group P 1
Cell dimensions
a, b, c (A) 45.61, 64.57, 82.07
a, b, c(o) 95.63, 101.09, 104.93
Resolution (A) 29.26–1.70 (1.70–1.73)
Rmerge 0.024 (0.429)
I/rI 46.3 (2.6)
Completeness (%) 95.4 (90.9)
Redundancy 3.3 (3.2)
No. of reflections 93 239 (9102)
Rwork/Rfree 0.180/0.226









Bond lengths (A) 0.011
Bond angles (°) 1.72
Ramachandran plot
In preferred regions (%) 98.2
In allowed regions (%) 1.8
Outliers (%) 0.0
PDB code 6Z2F
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dysregulation of O-GlcNAcylation caused by muta-
tions in the OGT gene is associated with a develop-
mental disorder, termed OGT-CDG [23]. This study
was aimed at identifying other genes that are required
for O-GlcNAcylation that are mutated in patients with






Fig. 4. Structural analysis of AGX1A229T. (A) Superposition of AGX1A229T A chain (blue cartoon) and AGX1wt A chain (grey cartoon; PDB:
1JV1 [40]). (B) Superposition of AGX1A229T B chain (blue cartoon) and AGX1wt A chain (grey cartoon; PDB: 1JV1 [40]). UDP-GlcNAc is
highlighted as stick model in the active site of AGX1wt A chain (Ca blue) and AGX1
A229T B chain (Ca grey). The electron density of
carbamidomethylated Cys251 in AGX1A229T B chain is shown as black mesh contoured to 2.5 r. (C) Structure superposition showing the
difference between AGX1A229T A chain (blue cartoon) and the AGX1wt B chain (grey cartoon; PDB: 1JV1 [40]) at the point of the A229T
mutation. R228, A/T229, G222 and UDP-GlcNAc are shown as a stick model. Structural shift induced by the mutation is indicated by the
arrow. (D) Structure presentation of AGX1wt showing the interaction between UDP-GlcNAc, Q196 and A229. A229 is replaced by threonine
and the side chain of the threonine is shown as sphere model. (E) Sequence and structure alignment of AGX1A229T and eukaryotic UAP1
orthologues at the point of the A229T mutation. The helix in AGX1A229T is shown in transparent cartoon representation with residues shown
as a line model. (F) Stereoscopic view of the structural changes of AGX1 caused by the A229T mutation. The AGX1A229T A chain (blue
cartoon) is superposed to the AGX1wt A chain (grey cartoon). The movement in the N-terminal domain caused by the A229T mutation is
indicated by the arrow. The main chain of M218 and G222 and the side chain of E44, R228 and A/T229 are shown as stick models. The
segment which connects A229, UDP-GlcNAc and the N-terminal domain is shown as blue ribbon.
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[46], a de novo, heterozygous UAP1 gene missense
mutation (NM_001324114:c.G685A:p.A229T) was
identified in a patient with abnormalities of cranium,
skeleton and nervous system. In this study, we demon-
strated that UAP1 A229 is stringently conserved in
eukaryotic UAP1 orthologues and the UAP1 A229T
mutation is predicted to be pathogenic by clinical
bioinformatic tools. Biochemical characterization
revealed that, compared to AGX1wt, AGX1A229T has
decreased stability and activity in producing UDP-
GlcNAc while pyrophosphorolysis activity is increased.
The stability and activity changes of AGX1 caused by
the A229T mutation could collectively result in
decreased UDP-GlcNAc and O-GlcNAcylation levels
in vivo, giving a phenotype in the patient that resem-
bles aspects of OGT-CDG. However, experiments with
CRISPR/Cas9 knock-in cell lines or animal model sys-
tems are required to investigate this.
Structural analysis revealed that the A229T muta-
tion induced both local and global structural changes.
R228 shifted by 1.2 A when A229 is mutated to thre-
onine, followed by the disruption of the hydrogen
bonds formed between R228 and E44. An allosteric
inhibitor targeting Trypanosoma brucei UAP1 was dis-
covered binding to the same site where R228 and E44
interact in human UAP1 (Fig. S4), and it was pro-
posed that the inhibition was achieved by stabilizing
the N-terminal domain in a conformation that pre-
vents UTP binding [47], suggesting that the R228-E44
interaction in AGX1 could be contributing to regula-
tion of activity. The R228-E44 interaction contributes
to the interaction between the N-terminal and catalytic
domains of AGX1wt, and disruption in the AGX1A229T
structure leads to a shift of the N-terminal domain
away from the catalytic domain. Accompanied by the
shift of the N-terminal domain, is the disruption of the
hydrogen-bonding interactions established through
Q112-R169-M218 between the N-terminal domain and
the key catalytic loop. Given both the R228-E44 and
the Q112-R169-M218 interactions are human AGX1
specific [40,68,69] and AGX1 is over ten times more
catalytically efficient than its fungal orthologues [45],
they could be one of the factors that contribute to the
high efficiency of AGX1, and disruption of them
together in the AGX1A229T structure could thus
explain the stability and activity differences between
AGX1wt and AGX1A229T. Threonine is one of the
common substitutions of alanine in nonsynonymous
coding single nucleotide polymorphisms (ncSNPs)
database [70], and alanine-to-threonine substitutions
have been associated with human conditions, such as
amyloid diseases [70] and PD [71]. It seems that the
mutation intolerance of UAP1 A229 in the
evolutionary context is not determined by the R228-
A229 interaction, as R228 is substituted to alanine in
plants (Fig. 2), but more dependent on the interaction
between the side chain of A229 and the main chain of
Q195/Q196 (Fig. 4D). Together with the observation
in fly models that the Drosophila UAP1 orthologue is
required for epithelial morphogenesis and nervous sys-
tem development [35–37], the UAP1A229T missense
mutation that results in considerable structure shifts
that underpin the observed stability and activity
changes of AGX1A229T could be a contributory factor
to the developmental delay observed in the patient.
Apart from being required for O-GlcNAcylation,
UDP-GlcNAc is also the precursor for glycosylphos-
phatidylinositol anchor synthesis, heparan sulphate
synthesis and N-linked glycosylation. Dysregulation of
these pathways has also been associated with develop-
mental disorders [72]. For instance, N-glycosylation is
a common post-translational modification in all three
kingdoms of life that regulates protein stability, pro-
tein processing and function [73]. DPAGT1/GPT
(Dolichol phosphate N-acetylglucosamine-phospho-
transferase) catalyses the first committed step of N-
linked glycosylation, using dolichol phosphate and
UDP-GlcNAc as substrates [74]. Mutations in the
DPAGT1 gene, which result in alteration of either pro-
tein activity, stability or structure, have been identified
as causing congenital disorders [75–78]. Mutations of
all the genes upstream of UAP1 in the HBP have been
identified as causing developmental disorders, and
decreases in O-GlcNAcylation levels are the common
and predominant molecular phenotype observed in
either patient-derived cells, mouse or fly models
[28,31–34]. N-linked glycosylation levels were
unchanged in cells carrying patient GFAT mutations
[33] and in mouse embryonic fibroblasts carrying a
GNA1 gene disruption [30]; however, they were
decreased in cells carrying patient PGM3 mutations
[33]. The pathways affected by the UAP1 A229T
mutation require further dissection using appropriate
models.
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